Placebo effects in developmental disabilities: Implications for research and practice
- 1 April 2005
- journal article
- research article
- Published by Wiley in Mental Retardation and Developmental Disabilities Research Reviews
- Vol. 11 (2) , 164-170
- https://doi.org/10.1002/mrdd.20065
Abstract
Recent clinical trials of secretin in children with autism showed robust placebo effects and no benefit of secretin over placebo. This article explores the reasons for the observed placebo effects, focusing on the heightening of positive expectancy by media attention and by the sensory experiences associated with intravenous injections. Comparisons are drawn with research involving other novel treatments and other clinical populations of children with developmental disabilities and neurobehavioral disorders. Research regarding mechanisms of placebo effects is reviewed, including patient and clinician attributes, expectancy effects, participation effects, changes in caregiver behavior, and conditioning. New evidence regarding the biological basis of placebo effects is briefly presented. Since placebo effects are ubiquitous and may operate by a variety of mechanisms, research design is critical in designing clinical trials and in evaluating other outcomes research. Measurement issues important for research in developmental disabilities are emphasized. Ethical concerns have been raised regarding the use of placebo in clinical research, but current analysis suggests that placebo controls are necessary and defensible on ethical grounds, if certain conditions are met. The study of placebo effects (“placebology”) holds great promise as a new area of research in therapeutics. The author's research in the potential augmentation of stimulant effects in children with attention deficit/hyperactivity disorder (ADHD) by adding placebo in open label is briefly presented. The placebo has always been integral to the practice of medicine, but advances in scientific medicine and medical ethics have diminished the role and use of placebo in practice. An innovative approach to the ethical use of placebo is proposed. © 2005 Wiley‐Liss, Inc. MRDD Research Reviews 2005;11:164–170.Keywords
This publication has 28 references indexed in Scilit:
- The Ethical Use of Placebo in Clinical Trials Involving ChildrenJournal of Child and Adolescent Psychopharmacology, 2004
- The Functional Neuroanatomy of the Placebo EffectAmerican Journal of Psychiatry, 2002
- Hyperbaric oxygen for children with cerebral palsy: a randomised multicentre trialThe Lancet, 2001
- Placebo Effects in AutismJournal of Developmental & Behavioral Pediatrics, 2000
- Lack of Benefit of a Single Dose of Synthetic Human Secretin in the Treatment of Autism and Pervasive Developmental DisorderNew England Journal of Medicine, 1999
- Clinical Hypnosis as a Nondeceptive Placebo: Empirically Derived TechniquesAmerican Journal of Clinical Hypnosis, 1994
- Conditioning as an Adjunct in the Pharmacotherapy of Lupus ErythematosusJournal of Developmental & Behavioral Pediatrics, 1992
- Conditioned suppression of humoral immunity in the rat.Journal of Comparative and Physiological Psychology, 1982
- THE MECHANISM OF PLACEBO ANALGESIAThe Lancet, 1978
- The Bottle of MedicineBMJ, 1952